The levels of troponin protein I do not decide the success rate of heart transplant
The latest study found that it is not accurate to predict whether a heart transplant will be successful through blood tests to check the health of the heart donor. The researchers said that if not paying enough attention to the results of the blood tests, it may increase the number of patients with advanced heart failure of heart transplantation. Recombinant protein plays its role in the research.
First author Dr. Snehal Patel said that heart transplantation therapy is a good therapy for patients with advanced heart failure, but the annual cases of transplant patients are only 2000–4000. Medicine associate professor Dr. Patel from Carleton Hospital and Monte Albert Einstein College of Medicine said people’s attention has focused on trying to make more people to sign organ transplant volunteer book. However, there is another problem, only one third of the donor hearts were transplanted.
What is challenged in blood tests is the level of protein which is called troponin protein I. The researchers produced recombinant rat proteins in the research. When the body shows myocardial infarction or other myocardial injury, the proteins will enter the bloodstream. If the heart looks good but the levels of troponin protein I are higher, many medical centers will reject the transplanted heart, fearing the markers showed unnormal heart function and such anomalies may be more pronounced in the experience porting process. Our aim is to prove whether this really is the case.
Study, the researchers show after nearly 11,000 US heart transplant patients were studied. The patients are over the age of 18. The researchers found no correlation between blood donors’ troponin I levels and mortality after transplantation for a year. In addition, donor blood troponin I levels had no significant effect on 30 days, one year, 3 years or 5 years of survival on organ recipients. Troponin levels seem to have no effect on the risk of serious complications.
The study has been published on June 21 in the journal Circulatory System: Heart Failure. This study shows that if excepting the troponin level, the other conditions are suitable, transplant centers should not refuse donor heart solely based on this. Like the role of recombinant Gp1ba in research, they researchers should refer to various data as they can.